Improving influenza vaccines for high-risk populations
CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations
['FUNDING_OTHER'] · UNIVERSITY OF GEORGIA · NIH-11041885
This study is working on creating better flu vaccines that last longer and protect more people, especially those who are at higher risk, like the elderly or those with health issues, so they can stay healthy during flu season.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF GEORGIA (nih funded) |
| Locations | 1 site (ATHENS, UNITED STATES) |
| Trial ID | NIH-11041885 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness and longevity of seasonal influenza vaccines, aiming to develop innovative vaccines that provide broad and lasting protection against the virus. The approach involves detailed immunologic assessments and iterative vaccine design, utilizing pre-clinical animal studies and early-phase clinical trials. The University of Georgia's Center for Influenza Vaccine Research specifically targets high-risk populations, ensuring that the most vulnerable groups receive the best possible protection. The program leverages a collaborative effort among experienced and emerging researchers, utilizing advanced facilities and resources.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals from high-risk groups, such as the elderly, immunocompromised individuals, and those with chronic health conditions.
Not a fit: Patients who are not at high risk for influenza complications or those who have already received effective seasonal vaccines may not receive significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective influenza vaccines that provide long-lasting immunity, particularly benefiting high-risk populations.
How similar studies have performed: Previous research has shown promise in developing improved influenza vaccines, but this specific approach aims to create a novel, broadly protective vaccine, making it a potentially groundbreaking effort.
Where this research is happening
ATHENS, UNITED STATES
- UNIVERSITY OF GEORGIA — ATHENS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROSS, TED — UNIVERSITY OF GEORGIA
- Study coordinator: ROSS, TED
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.